Curtis Layton
Chief Executive Officer at Protillion Biosciences, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Walt | M | 71 |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | 5 years |
Malek Faham | M | - |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | - |
Sean Kendall | M | - |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | - |
Trevor Squier | M | - |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Will Greenleaf | M | - |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Curtis Layton
- Personal Network